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be associated with signiﬁcant morbidity. This may reﬂect our current 
limitations in staging lung cancer, particularly in detecting early or 
occult metastases. Several recent studies have demonstrated the ability 
to detect circulating lung tumour cells by RT-PCR using several gene 
products and the prognositc value of this investigation. There have been 
few studies exploring the use of IHC to detect circulating tumour cells. 
In these studies, IHC was found to be inferior to RT-PCR. The aim of 
this study was to assess the utility of a novel cell separation method 
called RosetteSep to generate a concentrated pellet of non-hemato-
logic cells from peripheral blood, which would allow for potentially 
improved detection of circulating tumour cells by cellular morphology 
and IHC stains for CEA, CK19, TTF1 and Moc1 compared with RT-
PCR using mRNA products of the same genes.
Methods: Forty Stage III or IV, previously untreated, NSCLC patients 
were accrued at consultation at the Vancouver Cancer Centre (VCC). 
Twenty healthy volunteer subjects with no known prior malignancy, 
lung disease or ongoing infection were recruited by letter and poster 
and accrued at VCC. Each consented subject had a total of 17 ml of 
peripheral blood drawn. The ﬁrst 2 ml were discarded to avoid epi-
thelial cell contamination from the needle prick through the skin and 
the remaining 15 ml were collected into heparin tubes. CD45 positive 
cells were depleted using samples incubated with RosetteSep CD45 
Depletion Cocktail (StemCell Technologies Inc) to create cell concen-
trate pellet samples. Half of this sample was used to create a cell block 
and slices were taken for celular morphology and IHC using stains 
for CEA, CK19, TTF1 and Moc1. The second half of this sample was 
analyzed using RT-PCR to detect the gene products of CEA, CK19, 
TTF1 and Moc1. 
Results: IHC was reported positive if there was at least 30% cyto-
plasmic staining for CEA, CK19 and Moc1 and at least 30% nuclear 
staining for TTF1. Cell morphology was used to conﬁrm the presence 
of malignant cells in the cell block specimen. The results of RT-PCR 
were reported as a relative quantity of gene expression in each sample. 
The detection rate of circulating tumour cells in NSCLC patients by 
RT-PCR was comparable to the detection rates demonstrated in previ-
ous studies. The detection rate of circulating tumour cells by IHC was 
lower than with RT-PCR but the difference was not signiﬁcant. No false 
positives were noted in the healthy volunteers. 
Conclusions: This novel cell concentration method improved IHC 
detection of circulating tumour cells from peripheral blood samples of 
NSCLC patients. Further reﬁnement of this technique may prove that 
a smaller volume of blood is required for IHC detection of circulating 
tumour cells, allowing for better clinical applicability of this investiga-
tion. This may ultimately improve “staging” of patients to improve 
selection of patients for appropriate therapies. Finally, the creation of 
a cell block would allow for tissue banking for future IHC studies in 
NSCLC.
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Background: Current staging methods are imprecise for predicting 
the outcome of treatment of NSCLC. The goal of this project was to 
develop a gene expression proﬁle for stage I and II NSCLC that is able 
to identify patients that have a high risk of disease progression within 
2-3 years after initial diagnosis. 
Methods: We used whole-genome gene expression microarrays to 
analyze frozen-tumor samples from 172 patients (pT1&2, N0&1, MO), 
who had undergone complete surgical resection in 5 European institu-
tions. Randomly generated numbers were used to assign 2/3 of the 
samples to an algorithm training group with the remaining 1/3 set aside 
for independent validation. Cox proportional hazards models were used 
to evaluate the association between the level of expression and patient 
survival. We used risk scores and nearest centroid analysis to develop a 
gene-expression model for the prediction of treatment outcome. 10-fold 
cross validation was used to prevent model over-training.
Results: 72 genes that correlated with survival were identiﬁed by 
analyzing microarray data and risk scores. Based on the expression of 
these genes, patients in training and validation groups were classiﬁed 
as either high or low risk. Analysis of predicted risk groups revealed 
signiﬁcantly different survival distributions for patients in both the 
training set (p<0.001) and independent validation set (p=0.01). Genes 
in our prognostic signature are enriched for genes associated with im-
mune response, antigen binding and protein modiﬁcation/ubiquination. 
Conclusions: Our 72-gene signature is closely associated with overall 
survival of completely-resected NSCLC patients. 
